10-Q: Vaccinex Reports Q2 2024 Results, Highlights Progress in Alzheimer's and Cancer Programs

Sentiment:

Quarterly Report 14 August 2024 5:17 PM

Vaccinex, Inc. released its second quarter 2024 financial results, detailing ongoing clinical trial progress and financial updates, while also noting concerns about its ability to continue as a going concern.

Capital raiseThe company has raised approximately $7.9 million through private placements, a public offering, and the sale of Series A Preferred Stock during the six months ended June 30, 2024.The company intends to explore additional financing options in connection with the call of these warrants, which could include warrant inducement or exchange transactions.The company is projecting insufficient liquidity to sustain its operations and meet its obligations through one year following the date that the condensed financial statements are issued, indicating a need for further capital raising.

Worse than expectedThe company's financial results were worse than expected due to a significant net loss and a very low cash balance, raising concerns about its ability to continue as a going concern.The company is not in compliance with Nasdaq's minimum stockholders' equity requirement, indicating a worse than expected financial position.

Summary

Vaccinex, Inc., a clinical-stage biotechnology company, reported a net loss of $5.6 million for the three months ended June 30, 2024, and $9.5 million for the six months ended June 30, 2024.
The company's cash and cash equivalents stood at $0.2 million as of June 30, 2024, down from $1.5 million at the end of 2023.
Revenue for the three months ended June 30, 2024, was $232,050, and $336,400 for the six months ended June 30, 2024, primarily from collaboration agreements.
Research and development expenses decreased to $3.9 million for the three months ended June 30, 2024, and $7.2 million for the six months ended June 30, 2024, due to the winding down of the SIGNAL-AD trial and a pause in enrollment for the head and neck cancer trial.
The company is facing challenges in maintaining its Nasdaq listing due to not meeting the minimum stockholders' equity requirement, with an extension granted until September 30, 2024, to regain compliance.
Vaccinex is developing pepinemab for Alzheimer's disease, Huntington's disease, head and neck cancer, and pancreatic cancer, with positive topline data reported for the SIGNAL-AD trial.
The company has raised approximately $7.9 million through private placements, a public offering, and the sale of Series A Preferred Stock during the six months ended June 30, 2024.

Sentiment

Score: 4

Explanation: The document presents mixed signals. While there are positive clinical trial results, the company's precarious financial situation and the risk of delisting from Nasdaq significantly dampen the overall sentiment. The positive clinical data is promising, but the financial risks are substantial.

Positives

The SIGNAL-AD trial showed a statistically significant increase in brain metabolic activity with pepinemab treatment, suggesting potential benefits for patients with MCI due to AD.
The KEYNOTE B-84 study demonstrated promising results for pepinemab in combination with KEYTRUDA for head and neck cancer, particularly in PD-L1-low tumors.
The company has secured funding through private placements, a public offering, and the sale of Series A Preferred Stock, raising approximately $7.9 million.
The company has multiple ongoing clinical trials and collaborations, indicating active development of its product candidates.
The company has the option to call for cancellation the warrants to purchase shares of common stock that it issued in transactions in October 2023, November 2023, February 2024, and March 2024, for $0.0001 per warrant share.

Negatives

The company reported a net loss of $5.6 million for the three months ended June 30, 2024, and $9.5 million for the six months ended June 30, 2024.
The company's cash and cash equivalents are very low at $0.2 million as of June 30, 2024, raising concerns about its ability to continue as a going concern.
Vaccinex is not in compliance with Nasdaq's minimum stockholders' equity requirement and faces potential delisting if compliance is not regained by September 30, 2024.
The company has incurred significant losses and negative cash flows from operations since inception.
The company is projecting insufficient liquidity to sustain its operations and meet its obligations through one year following the date that the condensed financial statements are issued.

Risks

The company's ability to continue as a going concern is in doubt due to recurring losses and negative cash flows.
There is a risk of delisting from the Nasdaq Capital Market if the company fails to regain compliance with the minimum stockholders' equity requirement by September 30, 2024.
The company's financial position is precarious, with limited cash reserves and a need for additional financing.
The company's product candidates are still in development, and there is no guarantee of regulatory approval or commercial success.
The company is dependent on third-party manufacturers and suppliers, which could lead to delays or disruptions in the supply chain.
The company faces competition from other biotechnology companies developing treatments for similar diseases.

Future Outlook

The company expects to continue to incur significant losses for the foreseeable future as it continues its research and development efforts and seeks regulatory approvals for its product candidates. The company plans to finance its operations through public or private sales of equity, debt financing, or other capital sources.

Management Comments

The company believes that results of the SIGNAL-AD study demonstrate that pepinemab has a similar effect in Alzheimers to those previously described for a key outcome in Huntingtons disease, preventing the characteristic disease-related decline of brain metabolic activity in a brain region known to be affected early in disease progression.
The company believes that pepinemab may be most effective in patients with very early stage symptoms, e.g., Mild Cognitive Impairment (MCI) due to AD.
The company intends to call these warrants for cancellation within the applicable periods.
The company intends to explore additional financing options in connection with the call of these warrants, which could include warrant inducement or exchange transactions.

Industry Context

The company is operating in the competitive biotechnology industry, focusing on developing treatments for neurodegenerative diseases and cancer. The positive results from the SIGNAL-AD trial and the KEYNOTE B-84 study are significant as they address unmet needs in these areas. The company's approach of targeting SEMA4D is unique and could provide a competitive advantage if successful.

Comparison to Industry Standards

The reported ORR of 21.1% and median PFS of 5.79 months in the KEYNOTE B-84 study for PD-L1-low head and neck cancer patients are notably higher than historical response rates for ICI monotherapy, which are around 11.9% ORR and 2.2 months PFS.
The company's approach of targeting SEMA4D is unique compared to other companies developing treatments for neurodegenerative diseases and cancer.
The company's focus on early-stage MCI in AD aligns with the industry's growing recognition of the importance of early intervention in neurodegenerative diseases.
The company's financial situation is concerning, as many early-stage biotech companies face challenges in securing funding and achieving profitability, but the low cash balance is a significant concern.

Related Party Transactions

The company leases its facility from 1895 Management, Ltd., a New York corporation controlled by an entity affiliated with the company's chairman and major stockholder.
FCMI Parent Co. and Vaccinex (Rochester) L.L.C., which are controlled by board members, purchased shares of the company's common stock and accompanying warrants in the February 2024 offering.

Stakeholder Impact

Shareholders face the risk of significant losses due to the company's financial instability and potential delisting from Nasdaq.
Employees may be concerned about job security due to the company's financial challenges.
Patients may benefit from the company's clinical programs if the product candidates are successful.
Creditors face the risk of non-payment if the company's financial situation does not improve.
Suppliers may be concerned about the company's ability to pay for goods and services.

Next Steps

The company needs to regain compliance with Nasdaq's minimum stockholders' equity requirement by September 30, 2024.
The company intends to call for cancellation the warrants to purchase shares of common stock that it issued in transactions in October 2023, November 2023, February 2024, and March 2024.
The company will explore additional financing options in connection with the call of these warrants.
The company will continue to advance its clinical programs for pepinemab in Alzheimer's disease, head and neck cancer, and pancreatic cancer.
The company will continue to evaluate its development strategy in terms of business opportunity and other near-term clinical activities for Huntington's disease.

Key Dates

Date	Description
2020-05-08	The company received a loan under the Small Business Administration's Paycheck Protection Program.
2021-11-08	The company was awarded loan forgiveness of $876,171 and the remaining balance of the loan was refinanced.
2023-03-30	The company entered into a Stock Purchase Agreement, pursuant to which the Company issued and sold 23,693 shares of its common stock at a purchase price of $86.10 per share for aggregate gross proceeds of $2.04 million.
2023-09-25	The company effected a 1-for-15 reverse stock split of its issued shares of common stock.
2023-10-03	The company sold shares of common stock and warrants in a public offering.
2023-11-01	The company issued and sold private placement warrants to purchase 37,694 shares of common stock.
2024-02-06	The company entered into a securities purchase agreement pursuant to which we issued and sold 274,182 shares of our common stock together with private placement warrants to purchase up to 274,182 shares of common stock and (ii) pre-funded warrants to purchase up to 90,363 shares of common stock together with private placement warrants to purchase up to 90,363 shares of our common stock.
2024-02-19	The company effected a second reverse split of shares of the Company's common stock on a 1-for-14 basis.
2024-03-27	The company entered into a securities purchase agreement pursuant to which the Company issued and sold 193,000 shares of the Company's common stock in a public offering together with private placement warrants to purchase up to 193,000 shares of common stock in a concurrent private placement.
2024-03-28	The company entered into a securities purchase agreement with the Alzheimers Drug Discovery Foundation pursuant to which the Company sold shares of a newly designated series of convertible preferred stock, the Series A Preferred Stock, and warrants to purchase up to 229,057 shares of the Company's common stock.
2024-04-11	The company received a letter from the Listing Qualifications staff of Nasdaq notifying the Company that it no longer complies with the requirement under Nasdaq Listing Rule 5550(b)(1) to maintain a minimum of $2.5 million in stockholders equity.
2024-05-09	The company's stockholders approved the First Amendment to the 2018 Omnibus Incentive Plan.
2024-06-05	Nasdaq notified the Company that it has been provided an extension to regain and evidence compliance with the Equity Standard on or before September 30, 2024.
2024-06-30	The last patient completed their last visit in the SIGNAL-AD Phase 1b/2 study of pepinemab treatment for Alzheimers disease.
2024-07-31	SIGNAL-AD topline data was reported by Eric Siemers, MD, Principal Investigator of the SIGNAL-AD trial at the Alzheimer's Association International Conference in Philadelphia.
2024-08-09	As of this date, the registrant had 1,727,700 shares of common stock outstanding.
2024-08-14	The date of the filing of the quarterly report on Form 10-Q.
2024-08-30	The company has the option to call for cancellation the warrants to purchase shares of common stock that it issued in transactions in October and November 2023, and certain of the March 2024 warrants, for $0.0001 per warrant share.
2024-09-30	The deadline for the company to regain and evidence compliance with the Equity Standard.
2024-11-28	The company has the option to call for cancellation the warrants to purchase shares of common stock that it issued in transactions in February 2024 and certain of the March 2024 warrants, for $0.0001 per warrant share.

Keywords

Vaccinex, pepinemab, Alzheimer's disease, cancer, Huntington's disease, clinical trial, biotechnology, SEMA4D, Nasdaq, financial results, warrants, private placement, public offering

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.